GO
| HSI1 | 23,753.84 | 0.00 | -- |
| HSCEI1 | 7,981.54 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
AKESO (09926.HK) Plunges Nearly 24%; CLSA Says FDA Non-approval of Ivonescimab Meets Expectations
2026-11-16 10:33:52 AKESO (09926.HK) opened 14.95% lower in a gap-down this morning (16th) and once slumped nearly 32% in early trading to a low of HKD56.1. It is now trading at HKD62.6, down 23.94%, with trading volume surging to 35.2803 million shares, involving turnover of HKD2.162 billion. CLSA said in a research report that AKESO's partner Summit Therapeutics Inc. (SMMT.US) announced overnight (15th) that it had received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the biologics license application for its self-developed PD-1/VEGF bispecific antibody ivonescimab. The application, for use in combination with chemotherapy for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) previously treated with EGFR-TKI therapy, has not been approved for the time being. The FDA believes that although the global Phase III HARMONi study supporting the application met the primary endpoint of progression-free survival, it failed to demonstrate a statistically significant improvement in overall survival. The broker said the decision largely met market expectations and should therefore have a mildly negative short-term impact on AKESO's share price. CLSA maintained an "Outperform" rating on AKESO.(da/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |